Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial

• Status: Withdrawn
• Trial end date: 2013-06-01

Summary

To assess the maternal and infant safety of a single daily fixed-dose combination of TDF/FTC/EFV (Atripla®), compared to the association of LPV/r (Kaletra® or Aluvia®) and 3TC/ZDV (Combivir®) given to African women to prevent overall MTCT in populations practicing breastfeeding.

• Phase: Phase 3

Details

• Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
• Collaborators: Abbott; Gilead Sciences; GlaxoSmithKline; Merck Sharp & Dohme Corp.
• Treatments: Efavirenz; Emtricitabine; Lamivudine; Lamivudine, zidovudine drug combination; Lopinavir; Ritonavir; Tenofovir; Zidovudine